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Background: Riboflavin (RF) is essential for normal cellular metabolic activities. Human cells obtain RF from their
surroundings via a carrier-mediated process that involves RF transporters -1, -2 & -3 (hRFVT -1, -2 & -3; products of
SLC52A1, -A2 and -A3 genes, respectively). Little is known about the structural features of these transporters that are
important for their function/cell biology. Our aim in this study was to address these issues for the hRFVT-2, a
transporter linked to the neurodegenerative disorder Brown-Vialetto-Van Laere Syndrome (BVVLS).
Methods: We used comparative protein-structure modelling to predict residues that interact with two amino acids
known to be critical for hRFVT-2 function (the clinical mutants L123 and L339), site-directed mutagenesis, and
truncation approach in the human-derived brain U87 cell model.
Results: First we showed that the defect in the function of the L123 and L339 hRFVT-2 clinical mutants is related to
a reduction in protein stability/translation efficiency and to retention of the protein in the ER. Mutating V120 and
L121 (residues predicted to interact with L123) and L342 (a residue predicted to interact with L339) also led to a
significant inhibition in hRFVT-2 function (with no change in membrane expression); this inhibition was associated
with changes in protein stability/translation efficiency (in the case of V120A and L342A) and an impairment in
transport function (in the case of L121). Truncating the N- and C- terminals of hRFVT-2 led to significant inhibition
in RF uptake, which was associated with changes in protein stability/translation efficiency (it was also associated
with a partial impairment in membrane targeting in the case of the N-terminal truncation).
Conclusion: These investigations report on identification of residues/sequences in the hRFVT-2 protein that is
important for its physiological function and cell biology.
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The water-soluble vitamin B2 (Riboflavin, RF) is an in-
dispensable micronutrient for normal cellular function
and growth. In its biologically active forms, flavin adenine
dinucleotide (FAD), and flavin mononucleotide (FMN),
the vitamin plays key metabolic roles as an intermediate
in the transfer of electrons in biological oxidation-
reduction reactions. Such reactions are involved in
carbohydrate, protein and lipid metabolism as well as in
the metabolic conversion of vitamins B6 and B9 into* Correspondence: hmsaid@uci.edu
1Departments of Medicine, Physiology/Biophysics, University of California,
Irvine, CA 92697, USA
2Department of Veterans Affairs Medical Center, Long Beach, CA 90822, USA
© 2015 Subramanian et al.; licensee BioMed C
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.their biologically active forms [1]. Recent studies have
also attributed anti-inflammatory and antioxidant prop-
erties to RF [2-4]. RF deficiency and sub-optimal levels
have been observed in conditions like diabetes mellitus,
inflammatory bowel disease, and chronic alcoholism
[5-8]; it may also occur as a result of chronic use of
certain psychotropic agents [9]. Deficiency/sub-optimal
RF levels also occur in subjects with infantile Brown-
Vialetto-Van Laere Syndrome (BVVLS), a rare neuro-
logical disorder linked to mutations in hRFVT-2 and
hRFVT-3; [10-15]. Supplementation with high-doses of
RF brings a significant improvement in the clinical
symptoms of patients with this disorder [16,17].entral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and thus, must obtain this essential micronutrient from
their surroundings via transport across cell membranes.
This event has been known for quite some time to occur
via a specific and carrier-mediated process, but the mo-
lecular identity of the system (s) involved has only been
recently uncovered. There are three RF transporters that
operate in human cells, namely hRFVT-1, -2, and -3 (the
products of SLC52A1, SLC52A2 and SLC52A3 genes, re-
spectively) [18-21]. These transporters share significant
identity at the amino acid level, but are differentially
expressed in human tissues; they also show differences
in their capacity to transport RF [20,22]. Among these
transporters, hRFVT-2 appears to be the predominant
transporter expressed in brain tissue and is believed to
play a key role in regulating brain RF homeostasis [20].
Recent studies have linked mutations in hRFVT-2 to
BVVLS, thus providing some insight into structure-
function relationship of the hRFVT-2 protein [11,13-15].
Besides that, there is little known about structural fea-
tures of the hRFVT-2 protein that are important for its
function and cell biology. Our aim in this study was to
expand our knowledge in these areas, and we used a
comparative protein-structure modelling to predict resi-
dues that interact with two amino acids known to be
critical for hRFVT-2 function, i.e., L123 and L339 [13],
site-directed mutagenesis, and truncation approaches.
The human-derived brain U87 cells were used as a
model in these investigations since the hRFVT-2 protein
is predominantly expressed in the brain [20]. Our results
showed that the residues located at positions 120, 121
and 342 of the hRFVT-2 polypeptide as well as its N-
and the C- terminals to be important for function and cell
biology of the protein.
Materials and methods
Materials
Human -derived brain U87 cells were purchased from











The mutated DNA sequences are in bold face text.VA). GFP-C3 vector and DsRed-ER (ER-marker) were
from Clontech (Palo Alto, CA). 3H-RF (specific activity:
21.2 Ci/mmol, radiochemical purity: > 98%) was pur-
chased from Moravek Biochemicals (Brea, CA). DNA
oligonucleotide mutant primers were obtained from Sigma
Genosys. Molecular biology grade reagent and all other
chemicals were obtained from commercial vendors.
Methods
Site-directed mutagenesis and generation of the N- and
C-terminal truncated hRFVT-2 construct
Studies described in the manuscript was reviewed and
approved by our institution Research and Development
Committee. Point mutations in the open reading frame
(ORF) of hRFVT-2 were introduced using the Quick
Change site-directed mutagenesis kit (Stratagene, La
Jolla, CA). Overlapping primers containing the mutated
nucleotides to the specified mutation sites (Table 1) and
GFP-hRFVT-2 (WT) fused plasmid were used as a tem-
plate in site-directed mutagenesis and PCR conditions
were followed as described previously [23]. The N- and
C-terminal truncated hRFVT-2 constructs were gener-
ated by PCR using the primer combinations as shown in
Table 2 and conditions specified previously [23]. The
PCR products and the GFP-C3 vector were digested
with HindIII and SacII, and products were gel separated
and fused to generate in frame fusion proteins with the
GFP fusion to the N-terminus of each constructs. The
nucleotide sequences of all PCR-generated mutant and
truncated constructs were verified by DNA sequencing
(Laragen, Los Angeles, CA).
Cell culture, transient and stable transfection
U87 cells were maintained in DMEM (Invitrogen, CA)
supplemented with 10% FBS, penicillin (100,000 U/l), and
streptomycin (10 mg/l). For uptake studies, U87 cells were
grown in on 12-well tissue culture plates (Corning, NY).
For imaging studies, U87 cells were grown in on sterile
glass-bottomed Petri dishes (MatTek, Ashland, MA). Atd mutation sites in hRFVT-2









Table 2 Primer pairs used for generating the full-length, N- and C-terminal tail truncated constructs of hRFVT-2 by PCR
Construct Forward and reverse primers (5’-3’) Positions (bp) Fragment size (bp)
GFP-hRFVT-2[1–445] CCCAAGCTTATGGCAGCACCCACGCCCGCC; TCCCCGCGGGGAGTCACAGGGGTCTGCACA 1-1335 1335
GFP-hRFVT-2[1–424] CCCAAGCTTATGGCAGCACCCACGCCCGCC; TCCCCGCGGGAACATAGCAACAGCGCC 1-1272 1272
GFP-hRFVT-2[10–445] CCCAAGCTTATGGTGCTGACCCACCTGCTG; TCCCCGCGGGGAGTCACAGGGGTCTGCACA 28- 1335 1307
GFP-hRFVT-2[10–424] CCCAAGCTTATGGTGCTGACCCACCTGCTG; TCCCCGCGGGAACATAGCAACAGCGCC 28-1272 1244
Combination of primers and primer sequence used to generate each construct are shown. The restriction enzyme sites Hind III (boldface italic text) and Sac II
(boldface text) were added to the hRFVT-2 primer to enable subsequent sub-cloning into green fluorescent protein (GFP-C3) vector.
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GFP-hRFVT-2 (WT), mutated, and truncated constructs
with 3 μl of Lipofectamine 2000 (Invitrogen). After
24–48 hrs transient transfection cells were used for
imaging. For stable transfection, U87 cells were selected
using G418 (0.5 mg/ml) (Invitrogen) for 4–6 weeks as de-
scribed before [23,24].
Uptake assay
U87 cells transiently or stably expressing WT, mutated
and truncated constructs were grown in 12 well plates
and 3H-RF uptake assay was performed in Krebs-Ringer
(K-R) buffer at 37°C for 3 min (initial linear period; data
not shown) following established procedure [23,24]. 3H-
RF (14 nM) was added to the K-R buffer at the time of
uptake assay, and after 3 min the reaction was termi-
nated by ice-cold K-R buffer. We determined the radio-
active content in U87 cells using a Beckman Coulter
scintillation counter (Fullerton, CA). Protein content of
U87 cells was measured using a Bio-Rad DC Protein Assay
kit (Bio-Rad).
Real-time PCR analysis
One microgram of total RNA isolated from stable WT
and mutant constructs expressing U87 cells were treated
with DNase I and subjected to RT-PCR using iScript
cDNA synthesis kit (Bio-Rad). The mRNA expression
level was quantified using a real-time PCR machine with
specific primers for hRFVT-2 and β-actin (Table 1). Data
were normalized relative to β-actin using a relative rela-
tionship method [25].
Western blot analysis
Wild-type, mutated and truncated constructs expressing
whole U87 cell-lysate proteins were separated in
NuPAGE 4–12% Bis-Tris gradient minigels (Invitrogen),
proteins transferred onto immobilon polyvinylidene
difluoride membrane (PVDF) (Fisher Scientific), and
analyzed by western blotting. The blots were probed
with primary anti-GFP monoclonal antibody (1:1000)
(Clontech) and β-actin antibody (1:4000 dilutions)
(Santa Cruz, CA)]. After three washes with PBS-Tween
20, the blots were probed with the anti-mouse IRDye-800
and anti-rabbit IRDye-680 (both at 1:30,000 dilution)secondary antibodies. Immunoreactive specific bands
were detected using the Odyssey infrared imaging system
(LI-COR Bioscience, Lincoln, NE) and their intensity was
quantified using LI-COR software.
Confocal imaging of cells expressing the mutated and
truncated hRFVT-2 constructs
U87 cell monolayers were imaged using an inverted
Nikon C-1 confocal microscopy after 24-48 hrs of post-
transfection of GFP-hRFVT-2 (WT), mutated and trun-
cated constructs. The green fluorescent protein (GFP)
was excited with the 488 nm line from an argon ion
laser and the red fluorescent protein (DsRed) was ex-
cited with the 543 nm line from a HeNe ion laser and
emitted fluorescence was monitored at 515 ± 30 nm short
pass and 570 ± 50 nm long pass filters, respectively.
Images were captured with Nikon C-1 software (Nikon
Instruments Inc, NY).
Comparative protein structure modelling
For comparative modeling, we subjected the hRFVT-2
amino acid sequence to PSIPRED fold recognition pro-
gram (http://bioinf.cs.ucl.ac.uk/psipred) as described be-
fore [26]. Among the several templates, we chose the one
that covers almost the full-length of the transporter for
the most possible three-dimensional models. We further
evaluated the model by comparing the score of the energy
value to the experimentally determined energy value of
native protein of similar length by PROSA (https://prosa.
services.came.sbg.ac.at/prosa.php) [27]. The analysis sug-
gested L-fucose-proton symporter (PDB ID: 3O7Q) from
E.coli [28] as one of the most probable template, although
it shares 11% amino acid sequence identity with hRFVT-2.
The three dimensional structure of hRFVT-2 generated
was visualized by rasmol (www.rasmol.org).
Data presentation and statistical analysis
All uptake data are means ± SE of multiple separate
uptake determinations and are expressed in fmol/mg
protein/3 min. The Student’s t-test was used for statis-
tical analysis; P < 0.05 was considered statistically signifi-
cant. Kinetic parameters of the saturable component of RF
uptake were determined by subtracting the diffusing com-
ponent [determined from the slope of the line between
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(500 μM) and the point of origin] from total uptake. The
apparent Michaels-Menten constant (Km) and maximal
velocity (V max) were determined using non-linear re-
gression in Graph Pad Prism software (version 5.03). All
western blot analyses, real-time PCR assays, and imaging
studies were performed on at least three different occa-
sions with different batches of U87 cells.
Results
Generation of a comparative model for hRFVT-2 and
prediction of interacting residues
The hRFVT-2 is a 445 amino acids protein predicted to
have both the N- and C- terminals oriented toward the
cell interior [20,22]. Figure 1A shows a schematic repre-
sentation of the hRFVT-2 predicted secondary structure
highlighting the different mutations within its predicted
10 trans-membrane domains [20,22]. From the amino
acid sequence, we generated a comparative model for
hRFVT-2 as described previously [29]. The topology ofL
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Figure 1 Predicted membrane topology of hRFVT-2 and location of p
to have 10 transmembrane domains with both N- and C-terminal tails orie
are depicted in oval and rectangular shapes, respectively. B) Homology mo
clinically relevant mutations in the hRFVT-2 polypeptide. C) Comparison of
locations of the predicted amino acids are shown in box.hRFVT-2 determined from secondary structure predic-
tion by TMpred program (http://www.ch.embnet.org/
software/TMPRED_form.html) matches the relative ori-
entations of amino acids, as determined by comparative
three dimensional modelling. According to the in silico
model, amino acid L123 (which is mutated in BVVLS
leading to functional impairment; [13]) is predicted to
interact with amino acids F119, V120 and L121 of the
hRFVT-2 polypeptide. Similarly, amino acid L339 (an-
other clinical mutant found in BVVLS that led to im-
pairment in function; [13]) is predicted to interact with
L342 of hRFVT-2.
Role of the predicted amino acids in the function of
hRFVT-2
We examined the effect of the experimental mutants
F119, V120 and L121, which are predicted to interact
with the clinical mutant L123, on functionality of the
hRFVT-2. For that we stably expressed these mutants in
human U87 cells, then examined the initial rate of8 9 10
C-terminal
redicted and clinically relevant mutations. A) hRFVT-2 is predicted
nted intracellularly [20,22]. Predicted and clinically relevant mutations
delling of hRFVT-2 protein to show the location of predicted and
amino acid sequences of human, mouse and rat RF transporters. The
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[13], the L123 clinical mutant caused a significant
(P < 0.01) inhibition in RF uptake. In addition, a signifi-
cant inhibition in RF uptake was observed in cells express-
ing the mutants V120A and L121A (P < 0.01 and P < 0.05,
respectively) but not those expressing the F119A mutant
(for the latter reason the F119A mutant was not consid-
ered for further investigations) (Figure 2A). We also deter-
mined the effect of mutating the V120 residue of hRFVT2
on kinetic parameters of the RF uptake process. This was
done by examining the initial rate of RF uptake as a func-
tion of concentration in wild-type and V120 mutant ex-
pressing U87 cells. The results showed a marked decrease
in the Vmax of the RF uptake process (93.75 ± 8.19 and
51.80 ± 7.89 pmol/mg protein/3 min for wild-type and
V120 mutant, respectively) with no change in the appar-
ent Km (3.49 ± 0.57 and 2.98 ± 0.86 μM for wild-type and
V120 mutant, respectively). With regards to the clinical
mutant L339 and its interacting amino acid L342A, both
were found to cause a significant (P < 0.01) inhibition in
RF uptake by U87 cells (Figure 2B).
Effect of mutating the predicted (V120, L121 and L342)
and the clinically relevant (L123 and L339) residues on
level of expression of the hRFVT-2 mRNA and protein
To determine whether the reduced levels of 3H-RF up-
take observed with the different mutants is due to a
decrease in transcription, translation efficiency and/or
protein stability, we examined the mRNA and protein
levels of these mutants following expression in U87 cells;
this was done by mean of quantitative PCR and western
blot analysis, respectively. Results of the RT-PCR studies
showed no significant changes in the level of mRNA
expression of the different mutants when compared to
level of expression of the hRFVT-2 (WT) (Figure 3A & B).A
Figure 2 Effect of hRFVT-2 predicted and clinically relevant mutations
expressing WT, L123 and its interacting residues (F119, L120 and L121). B) R
residue (L342). 3H-RF (14 nM) uptake was performed in K-R buffer (pH 7.4)
experiments. *P < 0.01, **P < 0.05.Results of the western blot analysis, which were done
using whole U87 cell homogenates, showed that level of
protein expression of the clinical mutants L123P and
L339P in the total cell homogenates to be significantly
(P < 0.01) lower than that of hRFVT-2 (WT) (Figure 3C &
D). Similarly, mutating amino acid V120 (predicted to
interact with the clinical mutant L123) and amino acid
L342 (predicted to interact with clinical mutant L339)
were found to lead to a significant (P < 0.02 and P < 0.05,
respectively) decrease in level of protein expression in
whole cell homogenates compared to hRFVT-2 (WT)
(Figure 3C & D, respectively). On the other hand, level of
protein expression of the amino acid L121 mutant (which
also interacts with the clinical mutant L123) was not
affected.
Live cell confocal imaging of the predicted (V120, L121
and L342) and the clinically relevant (L123 and L339)
hRFVT-2 mutants in U87 cells
To determine the cellular expression of the experimental
and clinical hRFVT-2 mutants, we stably expressed
the mutant constructs in U87 cells, and performed
live cell confocal imaging. The results showed that
the GFP-hRFVT-2 (WT) protein is expressed at the
cell membrane and is also retained in intracellular
vesicular structures, as seen by us previously with
other cell-types [30]. Similarly, the experimental mutants
GFP-hRFVT-2[V120A], GFP-hRFVT-2[L121A] and GFP-
hRFVT-2[L342A] were found to be expressed at the cell
membrane and in intracellular vesicular structures in U87
cells (Figure 4). In contrast to the experimental mutants,
we found that the clinical mutants GFP-hRFVT-2[L123P]
and GFP-hRFVT-2[L339P] were retained intra-cellularlly
and they failed to reach the cell membrane (Figure 4). To
further validate the cellular localization of GFP-hRFVT-2B
on RF uptake by U87 cells. A) RF uptake by U87 cells stably
F uptake by U87 cells stably expressing WT, L339 and its interacting
at 37°C for 3 min. Data are means ± SE of at least 4 independent
A B
C D
Figure 3 Effect of hRFVT-2 predicted and clinically relevant mutations on level of expression of hRFVT-2 mRNA and protein in U87
cells. A&B) Total RNA was isolated from WT, predicted and the clinically relevant indicated mutant constructs stably expressing U87 cells and
quantitative real-time PCR was performed. Data (means ± SE) are from at least 3 independent experiments, normalized relative to β-actin. C&D)
Western blot was performed using equal amounts (60 μg) of total protein isolated from the wild-type, predicted and clinically relevant indicated
mutant constructs expressing cells cell-lysates. The blot was probed with the anti-GFP monoclonal and β-actin polyclonal primary antibodies. Data
(means ± SE) from at least 3 independent sets of experiment are expressed in arbitrary units. Inset is the image of a representative gel. *P < 0.01,
**P < 0.02, ***P < 0.05.
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co-transfected them with an endoplasmic reticulum
(ER) marker (ER-targeted red fluorescent protein con-
struct, DsRed-ER) and observed strong co-localization
with both GFP-hRFVT-2 clinical mutants and DsRed-ER
(Figure 5).
Role of the N- and C- terminals of hRFVT-2 in function
and cell biology
We examined the role of the N- and C- terminals in the
function and cell biology of hRFVT-2. This was done by
truncating these sequences (see Figure 6A, for trunca-
tion sites) and examining the effect of such truncations
on carrier-mediated RF uptake, level of hRFVT-2 protein
expression (western blot using whole cell homogenates),
and cellular expression of the different hRFVT-2 trun-
cated constructs (live cell confocal imaging) in U87 cells.
The results of the functional assay showed that truncat-
ing the N- and the C- terminals individually or togetherled to a significant (P < 0.02 and P < 0.01, respectively)
inhibition in the initial rate of carrier-mediated RF up-
take by U87 cells (Figure 6B). All three truncated con-
structs also showed a significant (P < 0.05 for all)
decrease in hRFVT-2 protein expression (Figure 6C).
The results of the confocal imaging studies showed that
a complete truncation of C-terminal tail of hRFVT-2
(GFP-hRFVT-2[1–424]) had no effect on cell surface ex-
pression (Figure 6D). On the other hand, the complete
removal of N- terminal tail of hRFVT-2 (GFP-hRFVT-2
[10–445]) led to a mixed phenotype, with some cells
showing expression at the cell surface while others
retained the protein in the ER (the latter was confirmed
by the significant overlap with DsRed-ER; Figure 6D).
When the C-terminal was truncated in addition to
the N- terminal (i. e., GFP-hRFVT-2[10–424]), the protein
showed complete retention in the ER (Figure 6D). Collect-
ively, these results show that the N- and C- terminal tails
are important for hRFVT-2 function and cell biology.
GFP-hRFVT-2[L339P] GFP-hRFVT-2[L342A]
GFP-hRFVT-2[L121A] GFP-hRFVT-2[L123P]GFPGFP-hRFVT-2 GFP-hRFVT-2[V120A]
Figure 4 Cellular distribution of the wild-type, predicted and clinically relevant hRFVT-2 mutants in U87 cells. Lateral (xy) sections of U87
cells stabley expressing WT, predicted and the clinically relevant hRFVT-2 mutants.
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There is little known about structural features of the
hRFVT-2 (a transporter whose mutation is linked to
BVVLS; [11,13-15]) that is important for its function
and cell biology. Our aim in this study was to address































Figure 5 Co-expression of hRFVT-2 clinically relevant mutants and Ds
(left) along with DsRed-ER (middle), displayed overlaid images (right). The co-structure modelling to predict residues that interact with
two residues that are mutated in patients with BVVLS
(L123 and L339) and are functionally impaired [13]. We
also used a truncation approach to examine the role of
the N- and C-terminals in function and cell biology of
hRFVT-2. We used the human brain U87 cells as a-ER Overlay
Red-ER in U87 cells. Co-expression of GFP-hRFVT-2 WT and mutants




Figure 6 (See legend on next page.)
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Figure 6 Effect of hRFVT-2 N- and C- terminal tail truncated constructs on RF uptake and on cellular distribution in U87 cells. A)
Schematic representation of the full-length hRFVT-2, and the N- and the C-terminal truncated constructs with GFP fused to the N- terminus
(GFP-hRFVT-2). B) 3H-RF uptake (14 nM) assay in a WT and truncated constructs transiently expressing U87 cells. Data represents the means ± SE
of at least 3 independent experiments. *P < 0.01, **P < 0.02. C) Western blot was performed using 60 μg of total protein isolated from the
wild-type, and truncated constructs expressing U87 cell-lysates. The blot was probed with the anti-GFP monoclonal and β-actin polyclonal primary
antibodies. Data (means ± SE) from 3 independent sets of experiment are expressed in arbitrary units. Inset is the image of a representative gel.
**P < 0.05. D) Co-expressing GFP-hRFVT-2 (WT) (left) along with DsRed-ER (middle), shown as overlaid image (right). Images were obtained after
24–48 hrs of post-transfection.
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brain tissues and is believed to play a key role in regulat-
ing brain RF homeostasis [20].
Our comparative protein-structure modelling pre-
dicted that amino acids F119, V120 and L121 (all are
within TM3) interacts with L123, and amino acid L342
(in TM8) interacts with the L339 of the hRFVT-2 poly-
peptide. Of those predicted amino acids, L121 and L342
are conserved in all three known human, mouse and rat
RF transporters (Figure 1C). We tested the role of all the
predicted residues in hRFVT-2 function by examining
the effect of mutating these sites on RF uptake. The re-
sults showed that mutating V120, L121 and L342 (but
not F119) led to a significant inhibition in RF uptake,
suggesting that these residues play a role in hRFVT-2
function. The inhibition in RF uptake upon mutating
V120, L121 and L342 was not due to an effect on cell
membrane expression of the hRFVT-2 (determined by
live cell confocal imaging), but rather appears to be due
to changes in protein stability/translation efficiency in
the case of the V120A and L342A mutants and due to a
defect in the transport function in the case of the L121
hRFVT-2 mutant. The kinetic study for the V120 mutant
showed a marked decrease in the Vmax of RF uptake by
the carrier-mediated process (with no change in appar-
ent Km). These results suggest that the V120 mutation
affected the number/activity of the hRFVT-2 protein
with no effect on its affinity. Our results also showed for
the first time that the cause of the defect in the transport
function of the L123 hRFVT-2 mutant is due to both a
reduction in protein stability/translational efficiency and
impairment in cell membrane expression of the protein
as indicated by the results of the western blots and the
live cell confocal imaging. Similarly, the L339 hRFVT-2
mutant showed a reduction in the level of hRFVT-2 pro-
tein expression in total cell homogenate, and also a de-
fect in cell membrane expression, suggesting changes in
protein stability/translation efficiency and impairment in
membrane targeting. The lack of expression of the L339
hRFVT-2 mutant at the cell membrane is similar to
what others have reported previously in renal epithelial
cells [15].
Many nutrient/substrate transporters contain sequences/
regions that are important for their function and targetingto cell membrane that are embedded within their N-
terminal [24,31], C-terminal [23,24,32,33], and/or trans-
membrane backbone [34,35]. In this study, we show that
both the N- (amino acids 1–9) and the C- terminal (amino
acids 425–445) sequences of the hRFVT-2 protein are im-
portant for its function and cell biology. This conclusion
is based on the following experimental observations. First,
the complete deletion of the C-terminal region of hRFVT-
2 led to impairment in transport function which was, at
least in part, due to the observed inhibition in protein sta-
bility/translation efficiency; deletion of the C-terminal,
however, did not affect plasma membrane expression of
the protein. Similarly, removal of the N-terminal sequence
of hRFVT-2 led to a significant impairment in RF uptake,
which again was associated with changes in protein stabil-
ity/translation efficiency; it was also, however, associated
with a partial impairment in membrane targeting. In con-
trast, removal of both the N- and the C- terminal se-
quences of hRFVT-2 lead to a significant inhibition in RF
uptake, a reduction in protein stability, and inhibition in
membrane expression due to retention of the protein in
the ER. Further studies are needed to determine the spe-
cific molecular determinants/motifs embedded within the
N- and the C- terminals that contribute to normal hRFVT-2
function and cell biology.
Conclusion
Results of these studies provide new insight into the
structural features of the hRFVT-2 protein that play a
role in its function and cell biology, and demonstrate an
important role for both the N- and C-terminal sequences
in this regard.
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